Antineoplastic anti-estrogenic non-steroidal agent.
The mechanism of antitumor effect is due to competitive binding to estrogen receptors in target organs and inhibition of the formation of the estrogen receptor complex with the endogenous ligand 17-r-estradiol.
The dosage regimen is set individually, depending on the indications, the patient’s condition and the antitumor therapy regimen used.
On the part of the digestive system: nausea, vomiting, increased activity of hepatic transaminases; In some cases – fatty liver infiltration, cholestasis, hepatitis.
From the side of the central nervous system: rarely – depression, dizziness, headache, retrobulbar neuritis.
From the side of the organ of vision: rarely – retinopathy, keratopathy, cataract.
From the hemopoietic system: rarely – thrombocytopenia, leukopenia.
On the part of the endocrine system: in women – endometrial hyperplasia, vaginal bleeding, hot flashes, weight gain; In men – impotence, decreased libido.
From the cardiovascular system: edema, thromboembolism, phlebitis.
Dermatological reactions: alopecia, rash, itching.
Other: pain in bones and lesions, increase in body temperature.
Mode of application
Assign inside as tablets. For breast cancer, take 20-40 mg 1-2 times a day; With endometrial cancer – 30-40 mg 1-2 times a day; With anovulatory infertility 10 mg 2 times a day for 4 consecutive days, starting from the 2nd day of menstruation. For subsequent 4-day cycles, you can increase the dose to 20-40 mg 2 times a day.
Restrictions on the use
Deep vein thrombosis and pulmonary embolism in a history of treatment with indirect anticoagulants coumarinic series, thrombocytopenia, leukopenia, hypercalcemia, hyperlipidemia, cataracts or visual impairment.